Pharma — Februar 2023
-
Gilead Sciences (GILD) Q4 2022 Earnings Call Transcript https://www.proinvestor.com/investornyt/935778/gilead-sciences-gild-q4-2022-earnings-call-transcript
-
Selskabernes forventninger - fredag den 3 februar
3.2.2023 06.30 • MarketWire •FREDAG DEN 3 FEBRUAR
======================
ALK-ABELLÓ (Q4)
ALK-Abelló venter i 2022 en organisk omsætningsvækst på 11-13 pct. i lokal valuta. Driftsresultatet før af- og nedskrivninger, EBITDA, ventes at lande på 675-750 mio. kr.
-
Is Gilead Sciences Stock a Screaming Buy After Its Strongest Results in 7 Years? https://www.proinvestor.com/investornyt/935865/is-gilead-sciences-stock-a-screaming-buy-after-its-strongest-results-in-7-years
-
Årsrapport 2022: ALK leverer salgsvækst på 13 % og indtjeningsvækst på 33 % i 2022
https://www.proinvestor.com/boards/110072 -
Regeneron Pharma Q4 Profit Declines; Adj. Total Revenues Up 14% https://www.proinvestor.com/investornyt/935909/regeneron-pharma-q4-profit-declines-adj-total-revenues-up-14
-
Is Moderna Stock a Buy Now? https://www.proinvestor.com/investornyt/935966/is-moderna-stock-a-buy-now
-
Gilead Sciences : FDA Approves Trodelvy In Pre-treated HR+/HER2- Metastatic Breast Cancer https://www.proinvestor.com/investornyt/936419/gilead-sciences-fda-approves-trodelvy-in-pre-treated-hr-her2-metastatic-breast-cancer
-
2 Reasons to Buy Johnson & Johnson, and 2 Reasons to Sell https://www.proinvestor.com/investornyt/936618/2-reasons-to-buy-johnson-amp-johnson-and-2-reasons-to-sell
-
Sandoz: FDA To Review BLA For Proposed Biosimilar Denosumab https://www.proinvestor.com/investornyt/936717/sandoz-fda-to-review-bla-for-proposed-biosimilar-denosumab
-
ALK-Abelló får lagt en tier oven i kursmålet hos Danske Bank https://www.proinvestor.com/investornyt/936732/alk-abello-far-lagt-en-tier-oven-i-kursmalet-hos-danske-bank
-
Johnson & Johnson's Latest Talcum Powder Development Could Be Costly https://www.proinvestor.com/investornyt/936862/johnson-amp-johnsons-latest-talcum-powder-development-could-be-costly
-
Could This Indication Provide a Lift for Bristol Myers Squibb's Stock? https://www.proinvestor.com/investornyt/936866/could-this-indication-provide-a-lift-for-bristol-myers-squibbs-stock
-
AstraZeneca: European Commission Approves Forxiga In Treatment Of Symptomatic Chronic Heart Failure https://www.proinvestor.com/investornyt/937342/astrazeneca-european-commission-approves-forxiga-in-treatment-of-symptomatic-chronic-heart-failure
-
Roche Announces Positive Results From Phase III Study Of Crovalimab In PNH https://www.proinvestor.com/investornyt/937336/roche-announces-positive-results-from-phase-iii-study-of-crovalimab-in-pnh
-
ALK-Abelló får hævet kursmålet til 130 kr. fra 120 kr. hos Danske Bank https://www.proinvestor.com/investornyt/937349/alk-abello-far-haevet-kursmalet-til-130-kr-fra-120-kr-hos-danske-bank
-
Lundbeck nedskriver på Vyepti-lagre og giver 2023-prognose https://www.proinvestor.com/investornyt/937422/lundbeck-nedskriver-pa-vyepti-lagre-og-giver-2023-prognose
-
Lundbecks indtjening slår forventningerne i markedet https://www.proinvestor.com/investornyt/937443/lundbecks-indtjening-slar-forventningerne-i-markedet
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind